Your browser doesn't support javascript.
loading
A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.
Casadesús, Ana Victoria; Deligne, Claire; Diallo, Béré Kadjdiatou; Sosa, Katya; Josseaume, Nathalie; Mesa, Circe; León, Kalet; Hernández, Tays; Teillaud, Jean-Luc.
Afiliação
  • Casadesús AV; Department of Chimeric Proteins, Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
  • Deligne C; Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
  • Diallo BK; The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
  • Sosa K; Sorbonne Université, Faculté De Médecine, UMRS 1135, Centre d'Immunologie Et Des Maladies Infectieuses Paris (Cimi-paris), Paris, France.
  • Josseaume N; Inserm U.1135, Immunology and Infectious Diseases Center (Cimi-paris), "Immune Microenvironment and Immunotherapy" Laboratory, Paris, France.
  • Mesa C; Department of Chimeric Proteins, Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
  • León K; Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
  • Hernández T; Inserm U.1138, Cordeliers Research Center, Paris, France.
  • Teillaud JL; UMRS 1138 Centre De Recherche Des Cordeliers, Sorbonne Université, Paris, France.
Oncoimmunology ; 9(1): 1770565, 2020 06 02.
Article em En | MEDLINE | ID: mdl-32923126
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-2 / Linfócitos T CD8-Positivos Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-2 / Linfócitos T CD8-Positivos Idioma: En Ano de publicação: 2020 Tipo de documento: Article